Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Key facts

Sponsor

Stanford University

Principal Investigator

Alexander Colevas

Stanford University

Intervention

Dabrafenib(drug)

Enrollment

1 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2019

Study locations (1)

• Stanford University, School of Medicine, Stanford, California, United States

Collaborators

Novartis Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rare odontogenic tumor

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07306962
  Virtual Lesion Segmentation and Mandibular Ameloblastoma Radiographic Safety Margin
  Alexandria University
• RECRUITINGPHASE2NCT06653517
  Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

See all trials for Rare odontogenic tumor →